Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: Mature results of an AGO phase III study

Journal of Clinical Oncology

Volumn 28, Issue 17, 2010, Pages 2874-2888

  Moebus, Volker ^a   Jackisch, Christian ^a   Lueck, Hans Joachim ^a   Du Bois, Andreas ^a   Thomssen, Christoph ^a   Kurbacher, Christian ^a   Kuhn, Walther ^a   Nitz, Ulrike ^a   Schneeweiss, Andreas ^a   Huober, Jens ^a   Harbeck, Nadia ^a   Von Minckwitz, Gunter ^a   Runnebaum, Ingo B ^a   Hinke, Axel ^a   Kreienberg, Rolf ^a   Konecny, Gottfried E ^a   Untch, Michael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CONGESTIVE HEART FAILURE; DEATH; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE SEQUENCE; DRUG EFFICACY; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INTENSE DOSE DENSE; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; THROMBOCYTOPENIA; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PACLITAXEL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956170294     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.7643     Document Type: Article

References (25)

1. Levine MN, Pritchard KI, Bramwell VHC, et al: Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 23:5166-5170, 2005 (Pubitemid 46224025)
2. Poole CJ, Earl HM, Hiller L, et al: NEAT Investigators and the SCTBG: Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 355:1851-1862, 2006
3. Roché H, Fumoleau P, Spielmann M, et al: Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. J Clin Oncol 24:5664-5671, 2006 (Pubitemid 46631307)
4. Martin M, Pienkowski T, Mackey J, et al: Breast Cancer International Research Group 001 Investigators: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313, 2005
5. Francis P, Crown J, Di Leo A, et al: Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 100:121-133, 2008 (Pubitemid 351480565)
6. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003 (Pubitemid 46594124)
7. Mamounas EP, Bryant J, Lembersky BC, et al: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP-B 28. J Clin Oncol 23:3686-3696, 2005
8. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003 (Pubitemid 46594092)
9. Hudis C, Citron M, Berry D, et al: Five year follow-up of INT C9741: Dose-dense chemotherapy is safe and effective. Breast Cancer Res Treat 94:S20, 2005 (suppl; abstr 41)
10. Hryniuk W, Levine MN: Analysis of dose intensity for adjuvant chemotherapy trials in stage 2 breast cancer. J Clin Oncol 4:1162-1170, 1986 (Pubitemid 16043865)
11. Norton L: A Gompertzian model of human breast cancer growth. Cancer Res 48:7067-7071, 1988
12. Skipper HE: Kinetics of mammary tumor cell growth and implications for therapy. Cancer 28: 1479-1499, 1971
13. Hudis C, Fornier M, Riccio L, et al: 5-year results of dose-intensive sequential adjuvant chemotherapy for woman with high-risk node-positive breast cancer: A phase II study. J Clin Oncol 17:1118, 1999
14. Möbus VJ, Untch M, du Bois A, et al: Dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥ 4+ LN): First results of an AGO trial. J Clin Oncol 22:6s, 2004 (suppl; abstr 513)
15. Möbus VJ, Lueck HJ, Thomssen C, et al: Dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide (ETC) in comparison to conventional dosed chemotherapy in high-risk breast cancer patients (≥ 4+ LN): Mature results of an AGO trial. Breast Cancer Res Treat 100:S20, 2006 (suppl 1; abstr 43)
16. Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA. 17. J Natl Cancer Inst 97:1262-1271, 2005 (Pubitemid 41535367)
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc A 135:185-207, 1972
19. Möbus V, Untch M, Thomssen C, et al: The impact of epoetin-alpha on anemia, red blood cell transfusions, and survival in breast cancer patients treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial). J Clin Oncol 25:18s, 2007 (suppl; abstr 569)
20. Hayes DF, Thor AD, Dressler LG, et al: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506, 2007 (Pubitemid 47572635)
21. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
22. Venturini M, Del Mastro L, Aitini E, et al: Dose-dense adjuvant chemotherapy in early breast cancer patients: Results from a randomized trial. J Natl Cancer Inst 97:1724-1733, 2005 (Pubitemid 41782282)
23. Bonneterre J, Roché H, Kerbrat P, et al: Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23:2686-2693, 2005 (Pubitemid 46179458)
24. Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008 (Pubitemid 351549913)
25. Praga C, Bergh J, Bliss J, et al: Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 23:4179-4191, 2005 (Pubitemid 46211324)